Vitamins K and D for Older Adults: The Evidence for a Critical Partnership

By James Aspinwall, co-written by Alfred Pennyworth (my trusted AI) — February 27, 2026, 09:30

Vitamins D and K are both fat-soluble, both involved in calcium metabolism, and both chronically under-discussed relative to their importance. For older adults, getting the balance right between these two vitamins isn’t optional — it’s the difference between calcium going into bones or into arteries.

The Core Mechanism: Calcium Traffic Control

Vitamin D increases calcium absorption from the gut. That’s well established. But vitamin D does not decide where that calcium ends up. That job belongs to vitamin K.

Vitamin D promotes the production of two vitamin K-dependent proteins:

Osteocalcin — binds calcium into bone matrix
Matrix Gla Protein (MGP) — prevents calcium from depositing in arterial walls

Both proteins require vitamin K to become activated (carboxylated). Without sufficient vitamin K, these proteins are produced but remain non-functional. The result is the calcium paradox: vitamin D increases calcium absorption, but without vitamin K, that calcium bypasses bones and accumulates in blood vessels.

This isn’t theoretical. Among 601 older adults studied, those deficient in both vitamins D and K had significantly increased left ventricular mass index — indicating adverse cardiac remodeling — and a 64% higher risk of all-cause mortality compared to those with adequate levels of both.

Vitamin D: What It Does and What It Doesn’t

Established Benefits

Bone health: Vitamin D is essential for calcium absorption. Deficiency causes osteomalacia in adults and increases fracture risk. This is the strongest evidence base.
Immune function: Vitamin D is an immunomodulatory hormone regulating both innate and adaptive immunity. Deficient hospitalized patients with pneumonia show more severe disease and greater mortality risk.
Mortality: Vitamin D deficiency (not mere insufficiency) correlates with increased all-cause mortality risk.

Cognitive Function — Mixed Evidence

Observational data is compelling: a 2023 dose-response meta-analysis found enhanced cognitive performance (global cognition, executive function, memory) at serum levels up to 60–70 nmol/L, with a stronger effect in women. A 2025 meta-analysis found a 1.2% reduction in dementia risk for every 10 nmol/L increase in serum vitamin D.

However, intervention trials tell a more cautious story. The VitaMIND randomized controlled trial (2025) found that vitamin D supplementation produced no measurable improvement in cognitive outcomes in older adults with mild to moderate deficiency. The VITAL trial ancillary study similarly showed no cognitive benefit from supplementation.

The pattern is familiar in nutrition research: low levels predict poor outcomes, but raising levels through supplementation doesn’t always reverse them. Vitamin D deficiency may be a marker of poor health rather than a direct cause of cognitive decline — or the relationship may require longer intervention periods than trials typically measure.

Dosing and Safety

Current recommendations for adults over 70: 800 IU/day minimum. The tolerable upper limit is set at 4,000 IU/day.

But “tolerable” deserves scrutiny. A systematic review and meta-analysis of RCTs found that 3,200–4,000 IU/day:

Outcome	Finding
Hypercalcemia risk	2.2x higher vs. control (4 cases per 1,000 individuals)
Fall risk	1.25x higher vs. control
Hospitalization risk	1.16x higher vs. control
Kidney stones	No significant difference
Mortality	No significant difference

In a 3-year trial of healthy older adults, hypercalcemia occurred in 0% of the 400 IU group, 3% of the 4,000 IU group, and 9% of the 10,000 IU group.

The safe maintenance dose supported by current evidence: 800–1,000 IU/day of vitamin D3, or 10 µg/day of calcifediol. Higher doses should be guided by blood testing and physician oversight, not guesswork.

Vitamin K: The Overlooked Half

K1 vs. K2

Vitamin K1 (phylloquinone) — found in green leafy vegetables. Primary role: blood clotting (coagulation).
Vitamin K2 (menaquinone) — found in fermented foods, animal products, and produced by gut bacteria. Primary role: directing calcium to bones and away from arteries.

For older adults, K2 is the more relevant form for bone and cardiovascular health. The most studied K2 subtype is MK-7 (menaquinone-7), found in natto (fermented soybeans) and available as a supplement.

Bone Health Evidence

A 3-year randomized placebo-controlled trial of 244 healthy postmenopausal women (ages 55–65) found that 180 µg/day of MK-7 decreased bone loss compared to placebo. The effect was most pronounced at the femoral neck and lumbar spine.

A 2025 systematic review and meta-analysis in Frontiers in Endocrinology confirmed that K2 supplementation improves bone turnover markers in postmenopausal osteoporosis, though the effect on fracture incidence requires larger trials.

The combination matters: in one study, vitamin K1 (1 mg/day) combined with calcium plus vitamin D was most effective in reducing bone loss at the femoral neck after 3 years among postmenopausal women — more effective than either vitamin alone or placebo. Out of 12 studies reviewed, 11 showed synergistic effects of vitamins D and K on bone fractures, BMD, and cardiovascular outcomes.

Cardiovascular Evidence

The vascular case for K2 centers on Matrix Gla Protein (MGP). Without K2, MGP remains uncarboxylated and cannot prevent arterial calcification. High levels of uncarboxylated MGP (dp-ucMGP) are a biomarker for cardiovascular risk.

In a study of 243 subjects aged 40–70 with vitamin K insufficiency, 180 µg/day of MK-7 for 3 years:

Significantly decreased markers of vitamin K insufficiency
Reduced carotid-femoral pulse-wave velocity (a measure of arterial stiffness)
Maintained arterial flexibility, while the placebo group became stiffer

Joint deficiency in both vitamins D and K has been associated with higher blood pressure and increased hypertension risk, suggesting the combination is relevant to cardiovascular prevention as well.

The Warfarin Complication

This is critical for older adults, many of whom take warfarin (Coumadin) for atrial fibrillation, deep vein thrombosis, or mechanical heart valves.

Warfarin works by inhibiting vitamin K recycling. Vitamin K supplementation can reduce warfarin’s anticoagulant effect, potentially increasing clot risk. For decades, patients on warfarin were told to avoid vitamin K.

The current understanding is more nuanced:

Consistent vitamin K intake is more important than low intake. Wild fluctuations in dietary vitamin K cause unstable INR readings and increase both bleeding and clotting risk.
A study in Blood found that low-dose vitamin K supplementation (100–150 µg/day) actually improved INR stability in patients with previously erratic warfarin response — because it eliminated the variable of unpredictable dietary intake.
Many warfarin patients are vitamin K depleted as a result of outdated dietary restriction advice, which paradoxically increases their cardiovascular and bone risk.

Bottom line for warfarin users: Do not start or change vitamin K supplementation without coordinating with the prescribing physician. But the old advice to simply avoid vitamin K is now considered outdated.

Newer anticoagulants (DOACs like apixaban and rivarelbine) do not interact with vitamin K, making K2 supplementation straightforward for patients on these medications.

Practical Guidance

Testing

25-hydroxyvitamin D (25(OH)D): The standard blood test for vitamin D status. Target range: 50–75 nmol/L (20–30 ng/mL) for most older adults. Below 30 nmol/L is deficiency.
dp-ucMGP (desphospho-uncarboxylated Matrix Gla Protein): Functional marker of vitamin K insufficiency. Not yet routine but increasingly available. Elevated levels indicate insufficient K2 to activate MGP.

Dietary Sources

Vitamin D:

Fatty fish (salmon, mackerel, sardines)
Egg yolks
Fortified dairy and plant milks
Sunlight exposure (limited utility in older adults due to reduced skin synthesis)

Vitamin K2 (MK-7):

Natto (by far the richest source: ~1,000 µg per 100g)
Hard cheeses (Gouda, Edam)
Egg yolks
Dark chicken meat
Fermented foods (sauerkraut, some yogurts — modest amounts)

Vitamin K1:

Kale, spinach, broccoli, Brussels sprouts
These primarily support clotting, not calcium metabolism

Supplementation

Nutrient	Evidence-Supported Dose	Notes
Vitamin D3	800–1,000 IU/day	Higher doses only with blood monitoring
Vitamin K2 (MK-7)	180 µg/day	Based on 3-year RCT data
Combined D3 + K2	Both at above doses	Synergistic for bone and vascular health

Take both with a meal containing fat — they are fat-soluble and require dietary fat for absorption.

What the Evidence Does Not Yet Support

Vitamin D megadosing (>4,000 IU/day) for cognitive protection — observational associations have not translated to intervention benefits, and higher doses increase adverse event risk.
Vitamin K2 as a standalone treatment for osteoporosis — it improves bone turnover markers but has not been shown to reduce fracture incidence independently in large trials.
Combined D + K supplementation reversing established arterial calcification — K2 can slow progression and maintain flexibility, but reversing existing calcification is unproven.

The Bottom Line

For older adults, vitamins D and K are not independent supplements — they are two halves of a calcium management system. Vitamin D without adequate K risks the calcium paradox: more calcium absorbed, but deposited in the wrong places. K without adequate D means insufficient calcium to work with in the first place.

The evidence supports modest, consistent supplementation of both — 800–1,000 IU of D3 and 180 µg of K2 (MK-7) daily — as a well-tolerated strategy for supporting bone density and arterial health. Neither vitamin is a magic bullet, but together they address a fundamental metabolic need that diet alone often fails to meet in aging populations.